PET-CT Predicting Segement Specific Lymph Nodes Metastasis

Trial Title: PET-CT Predicting Segement Specific Lymph Nodes Metastasis

NCT ID: NCT05970913

Condition: Non Small Cell Lung Cancer
Lymph Node Metastasis
Positron Emission Tomography

Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Lymphatic Metastasis

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Summary: This study is a multicenter prospective clinical study that aims to evaluate the predictive value of preoperative PET-CT results (such as SUV uptake, size of tumor lymph nodes, and differences in FDG uptake compared to surrounding tissues) for lymph node metastasis in patients with non-small cell lung cancer. During surgery, all patients underwent systematic mediastinal lymph node dissection. The final pathological results were used to assess the predictive value of PET-CT for segment-specific lymph node metastasis.

Criteria for eligibility:

Study pop:
Patients had non small cell lung cancer received surgery and systematic lymph node dissection.

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion. - Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1. - No enlarged mediastinal lymph nodes observed on preoperative contrast-enhanced CT. - Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery. - Systematic lymph node dissection performed during surgery. - No prior radiotherapy or chemotherapy for initial treatment. - No history of malignant tumors. Exclusion Criteria: - Locally advanced or distant metastasis. - Pleural dissemination observed during surgery. - History of malignant tumors. - Received neoadjuvant therapy. - Systematic lymph node dissection not performed during surgery. - Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

Gender: All

Minimum age: 20 Years

Maximum age: 80 Years

Healthy volunteers: No

Locations:

Facility:
Name: Shanghai Cancer Center

Address:
City: Shanghai
Country: China

Status: Recruiting

Contact:
Last name: Hang Li
Email: drlihang@163.com

Start date: November 1, 2023

Completion date: December 1, 2024

Lead sponsor:
Agency: Fudan University
Agency class: Other

Source: Fudan University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05970913